Tech Company Financing Transactions

Iterum Therapeutics Funding Round

Iterum Therapeutics, based in Chicago, secured $65 million from Arix Bioscience, Pivotal bioVenture Partners and Advent Life Sciences.

Transaction Overview

Company Name
Iterum Therapeutics
Announced On
5/20/2017
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series B
Investors

Arix Bioscience (Lead Investor) (Mark Chin)

Pivotal bioVenture Partners (Lead Investor) (Tracy Saxton)

Advent Life Sciences (Shahzad Malik)

Bay City Capital

Canaan Partners (Brent Ahrens)

Domain Associates

Frazier Healthcare Partners (Patrick Heron)

New Leaf Venture Partners (Ron Hunt)

Sofinnova Ventures (James Healy)

Proceeds Purpose
The proceeds of this financing will be used for production of clinical supplies and registration batches, expanding the chemistry, manufacturing and control and development organizations and execution of the uncomplicated urinary tract infections Phase 3 pivotal program.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 S Wacker Dr. 650
Chicago, IL 60606
USA
Phone
(312) 778-6070
Website
www.iterumtx.com
Email Address
Not Recorded
Overview
Iterum Therapeutics Limited is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives.
Profile
Iterum Therapeutics LinkedIn Company Profile
Social Media
Iterum Therapeutics Company Twitter Account
Company News
Iterum Therapeutics News
Facebook
Iterum Therapeutics on Facebook
YouTube
Iterum Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Corey Fishman
  Corey Fishman LinkedIn Profile  Corey Fishman Twitter Account  Corey Fishman News  Corey Fishman on Facebook
Chief Financial Officer
Judy Matthews
  Judy Matthews LinkedIn Profile  Judy Matthews Twitter Account  Judy Matthews News  Judy Matthews on Facebook
Chief Scientific Officer
Michael Dunne
  Michael Dunne LinkedIn Profile  Michael Dunne Twitter Account  Michael Dunne News  Michael Dunne on Facebook
Vice President
Thomas Loughman
  Thomas Loughman LinkedIn Profile  Thomas Loughman Twitter Account  Thomas Loughman News  Thomas Loughman on Facebook
VP - Bus. Development
John White
  John White LinkedIn Profile  John White Twitter Account  John White News  John White on Facebook
VP - Operations
Benjamin Pe
  Benjamin Pe LinkedIn Profile  Benjamin Pe Twitter Account  Benjamin Pe News  Benjamin Pe on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/20/2017: EAT Club venture capital transaction
Next: 5/20/2017: Upfront Healthcare Services venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.